Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.54 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.54 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.54 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.54 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.54 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19150630 | 0.88 | GRIN2D (0.55) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2257606 | 0.85 | LMNA (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19149692 | 0.83 | LMNA (0.72) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL8087323 | 0.83 | NPC1 (0.64) | POLBLMNAALDH1A1GAAHTT | |
| SCHEMBL2945737 | 0.81 | MEN1 (0.53) | POLBLMNAALDH1A1GAAHTT | |
| SCHEMBL25025703 | 0.80 | HSD11B1 (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19149542 | 0.80 | LMNA (0.56) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19173888 | 0.80 | ALDH1A1 (0.65) | LMNAHSD11B1ALDH1A1GAAHTT | |
| SCHEMBL19148495 | 0.80 | LMNA (0.70) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL4713929 | 0.79 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-2887952-B1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-15 | — | — | EP | disclosed |
| EP-3405183-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | Arisan Therapeutics Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| US-7749997-B2 | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors | ASTRAZENECA AB (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| EP-1966221-A1 | PYRIMIDO- [4, 5-]-OXAZINES FOR USE AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008007835-A1 | 2,4-QUINAZOLINE DERIVATIVES HAVING ACTIVITY TO T-TYPE CALCIUM CHANNEL AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007071966-A1 | PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-5424414-A | Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids | ABBOTT LABORATORIES (US) | 1995-06-13 | — | — | US | disclosed |
| US-5424414-A | Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids | ABBOTT LABORATORIES (US) | 1995-06-13 | — | — | US | disclosed |
| US-5424414-A | Haptens, tracers, immunogens and antibodies for 3-phenyl-1-adamantaneacetic acids | ABBOTT LABORATORIES (US) | 1995-06-13 | — | — | US | disclosed |
| EP-0654093-A1 | DETECTING AND AMPLIFYING TARGET NUCLEIC ACIDS USING EXONUCLEOLYTIC ACTIVITY | ABBOTT LABORATORIES (US) | 1995-05-24 | — | — | EP | disclosed |
| EP-0646180-A1 | METHODS FOR INACTIVATING NUCLEOTIDE SEQUENCES AND METAL CHELATES FOR USE THEREIN | ABBOTT LABORATORIES (US) | 1995-04-05 | — | — | EP | disclosed |
| WO-1995006756-A2 | OLIGONUCLEOTIDES AND METHODS FOR THE DETECTION OF $i(CHLAMYDIA TRACHOMATIS) | ABBOTT LABORATORIES (US) | 1995-03-09 | — | — | WO | disclosed |
| WO-1994029329-A1 | HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR 3-PHENYL-1-ADAMANTANEACETIC ACIDS | ABBOTT LABORATORIES (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994029329-A1 | HAPTENS, TRACERS, IMMUNOGENS AND ANTIBODIES FOR 3-PHENYL-1-ADAMANTANEACETIC ACIDS | ABBOTT LABORATORIES (US) | 1994-12-22 | — | — | WO | disclosed |
| WO-1994003636-A1 | DETECTING AND AMPLIFYING TARGET NUCLEIC ACIDS USING EXONUCLEOLYTIC ACTIVITY | ABBOTT LABORATORIES (US) | 1994-02-17 | — | — | WO | disclosed |
| WO-1993020241-A1 | METHODS FOR INACTIVATING NUCLEOTIDE SEQUENCES AND METAL CHELATES FOR USE THEREIN | ABBOTT LABORATORIES (US) | 1993-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | POLB 2779/4885GRIN2D 3988/4885GRIN3B 2211/4885 |
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | POLB 1159/4885GRIN2D 600/4885GRIN3B 200/4885 |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | DGAT1, DGAT2, ACAT2 | POLB 3218/4885GRIN2D 1166/4885GRIN3B 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.